Diablo Clinical Research LLC

Diablo Clinical Research conducts comprehensive Phase 1-3 clinical trials, focusing on innovative solutions for diabetes management while providing a professional environment for healthcare services. Founded in 1995 in Walnut Creek, US, Diablo Clinical Research specializes in clinical trial operations, supporting the development of therapeutic products. The company has maintained a consistent focus on enhancing its clinical trial capabilities. The founder of the company has an extensive background in clinical research, having previously founded other research-oriented businesses.

The firm has engaged in a total of 1 deal, with the most recent deal dated February 18, 2025. Diablo Clinical Research specializes in conducting Phase 1-3 clinical trials across various therapeutic areas, with a strong emphasis on diabetes management. The facility provides high-quality healthcare services to patients in a professional and confidential environment, supporting the development of medications and devices to address diverse health issues. Their core offerings revolve around the recruitment and management of clinical study participants, ensuring a representative sample of the community.

With a focus on accurate data collection and management, Diablo Clinical Research serves a broad client base, including pharmaceutical and biotechnology companies seeking to validate and improve their therapeutic products. The company operates mainly within the United States, catering to clients in both metropolitan and regional areas interested in advancing medical research. Diablo Clinical Research generates revenue primarily through contracts with sponsors for their clinical trial services. The company engages in direct partnerships with pharmaceutical and medical device companies, providing them with valuable data to support the development and approval of new therapies.

Revenue is structured around project-based agreements, where clients compensate the facility for participant recruitment, study management, and data analysis. These transactions typically involve milestone payments tied to specific phases of the clinical trials, enhancing the financial stability of the organization. The focus on providing reliable and timely data services positions Diablo Clinical Research as a trusted partner in the clinical research sector. In February 2025, Flourish Research, a portfolio company of Genstar Capital Partners, acquired Diablo Clinical Research.

This acquisition is aimed at enhancing Flourish Research's therapeutic research facilities and expanding its footprint in the healthcare industry. Future growth strategies may include an expansion into new markets and geographic regions, though specific details about those plans have not been disclosed.